profit from every A$100 of sales.
A$0A$100
Integral Diagnostics
A$1.70-0.87% today
-35.6% in 1 year
1-year low A$1.701-year high A$2.68
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay A$135.95 for every A$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Integral Diagnostics sold, what it kept, and what it did with the cash.
Sales went from A$359 million in 2022 to A$627 million in 2025, with A$4.67 million of profit last year.
SalesProfit
Integral Diagnostics handed back more cash to shareholders than it generated last year.
A$15M
Free cash flow 2025A$14M
Bought back its own shares–
Paid as dividendsA$15M
Cash vs. debtA$52M vs. A$585M
Integral Diagnostics vs. similar companies
Integral Diagnostics grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from A$100 of sales | Sales growth a year | Price per A$1 of profit |
|---|---|---|---|
| Integral Diagnostics | 135.9× · Very expensive | ||
 Thermo Fisher Scientific | 39.7× · Expensive | ||
 Danaher | 45.8× · Expensive | ||
 WuXi AppTec | 26.5× · Fair price | ||
 Lonza Group | No profit yet |
AI analysis
An AI analyst reads Integral Diagnostics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 359 | 440 | 470 | 627 | |
| 340 | 419 | 447 | 599 | |
| 36 | 39 | 42 | 58 | |
| 70 | 92 | 7 | 88 | |
| 15 | 25 | -61 | 5 | |
| 0.07 | 0.11 | -0.26 | 0.02 | |
| 94.6% | 95.2% | 95.1% | 95.5% | |
| 10.2% | 8.9% | 9.0% | 9.2% | |
| 4.1% | 5.7% | -12.9% | 0.7% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 783 | 839 | 744 | 1,426 |
| Cash | 123 | 34 | 42 | 52 |
| Total debt | 341 | 365 | 358 | 585 |
| Total liabilities | 436 | 466 | 443 | 733 |
| 347 | 373 | 302 | 693 | |
| 212 | 236 | 233 | 307 | |
| 3.4% | 4.6% | -4.3% | 1.7% | |
| 4.2% | 6.7% | -20.1% | 0.7% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 28 | 44 | 24 | 60 | |
| 9 | 27 | 42 | 14 | |
| Dividends paid | 21 | 13 | 14 | 15 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 135.9×
- –
- –
- 1.1×
- 1.0×
- 45.3×
- 13.3×
- 2.2%
- 0.7%
- 2.4%
Profitability
- 95.5%
- 9.2%
- 0.7%
- –
- 1.7%
- 1.4%
- –
- –
- –
- –
Growth
- +20.5%
- −38.6%
- –
- –
- +13.2%
Financial health
- 6.1×
- 0.84
- –
- 1.6×
- 0.68
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 958
Bottom 49%of 888
Bottom 5%of 600
Top 27%of 889
Top 41%of 987
2.4%of the share price, paid each year
On $1,000 invested$24a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
330.8% of its profit
Room to growStretchedMore than it earns: 110.3%
News
Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividendSeeking Alpha · Oct 24, 2026Global X 20+Yr US Treasury Bd Idx ETF Hdgd Unts declares CAD 0.193 dividendSeeking Alpha · Oct 24, 2026Global X 3-10 Year U.S. Treas Bd Idx ETF CAD Hdg declares CAD 0.20 dividendSeeking Alpha · Oct 24, 2026Global X 3-10 Year U.S. Treasury Bond Idx ETF US$ declares $0.20 dividendSeeking Alpha · Oct 24, 2026Global X 1-3Yr US Treasury Bd Idx ETF Unhdgd Unts declares CAD 0.189 dividendSeeking Alpha · Oct 24, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
33No pass
Philip Fisher
33No pass
Peter Lynch
35No pass
Joel Greenblatt
3No pass
Charlie Munger
21No pass
Terry Smith
33No pass
Questions about Integral Diagnostics
Is Integral Diagnostics a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Integral Diagnostics AI analysis
What does Integral Diagnostics do?
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It is in Diagnostics & Research, based in Melbourne, VIC, Australia, with 3,000 employees.
Does Integral Diagnostics pay a dividend?
Yes. At today's price the dividend is 2.4% a year. In 2025 it paid out A$15.5 million in dividends.
Is Integral Diagnostics stock halal?
No. Integral Diagnostics does not pass our halal screen: its debt is 92% of its market value, at or above the 33% limit. How we check
How has Integral Diagnostics stock done over the past year?
Down 35.6% over the past twelve months, to A$1.70. It traded between A$1.70 and A$2.68 and is 36.6% below its high.
Who are Integral Diagnostics's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, WuXi AppTec and Lonza Group. The peers table on this page compares their profit, growth and price with Integral Diagnostics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.